Hello Mr.,
We are working with our Canadian marketing partner, Paladin, on forecasts for Canadian sales.
I can tell you that there will be approximately 7,900 new cases of bladder cancer diagnosed in Canada this year. Of these, approximately 70% will be the non-muscle-invasive form of bladder cancer and 30% of these will be refractory to BCG (this is our target population). The prevalence is approximately 10 times the incidence, which adds to the potential patient population that could receive Urocidin treatment. Each of these patients would receive 12 doses on average, and the expected pricing could be in the range of $2,000 per dose.
The carrying cost of the Human Health business and remaining corporate infrastructure after the sale of Animal Health is expected to be less than $1 million per month. This does not include the cost associated with another Phase III trial, if required. The Company expects to have licensing partners in place in major markets to defray this cost (such deals are expected to include up-front payments and milestones). Several parties are engaged in partnering discussions with us.
Following Canadian market launch, the revenues from product sales will offset the monthly burn.
In classifying the share offering as "small", I was referring to the dollar amount.
Sincerely,
Jennifer
From:
: Shea, Jennifer
Sent: Wed Aug 07 16:23:47 2013